Clinical Trial

Plant-Based Foods and (Poly)Phenol Supplementation in Gut Microbiota Modulation, Body Weight, and Cardiometabolic Risk

Study acronym: PREDIET-ARAC
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 28, 2025 (before its estimated June 3, 2026 completion). Its status may not reflect the trial's current state.
Summary
This single-blind, randomized controlled trial aims to evaluate the effects of increased dietary polyphenol intake-either through a healthy plant-based diet (PBD) or supplementation-on body weight and cardiometabolic risk factors in adults with overweight or obesity. A total of 99 participants (aged 25-45 years, BMI 25-35 kg/m²) with cardiovascular risk factors will be recruited from local health centers and randomly assigned (1:1:1) to one of three intervention groups for 12 weeks: (1) a healthy PBD rich in polyphenols, with supplemental apple, blueberries, hazelnuts, extra-virgin olive oil, and coffee provided at no cost to the participant (2) a healthy diet plus polyphenol supplementation (≈30g/day) from maqui , green tea, olive leaf, cranberry, and grape extracts, or (3) a control group receiving placebo and standard healthy diet recommendations. All groups will follow a caloric deficit. Dietary intake will be assessed using three 24-hour dietary recalls at baseline and 12 weeks, with polyphenol intake estimated via the Phenol-Explorer database. Data collection will include lifestyle questionnaires, anthropometric and bioimpedance measurements, blood pressure assessments, physical activity monitoring via accelerometers, and strength evaluations. Blood samples will be analyzed using a large-scale targeted metabolomics approach (UHPLC-MS/MS) to identify metabolic signatures, particularly those linked to gut microbiota. Faecal samples will be collected at baseline and visit 3. Findings will provide insights into how dietary polyphenols-either from whole foods or supplementation-affect obesity-related outcomes and cardiometabolic risk, potentially unveiling gut microbial biomarkers as future therapeutic targets. This study aims to contribute to strategies for obesity and cardiometabolic risk prevention and treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-28; most recent amendment 2025-11-26.
Status change: Enrolling by Invitation → Active, Not Recruiting 2025-11-26
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-08-19
Trial Details
NCT Number NCT06911346
Lead Sponsor Universidad Catolica de Temuco
Collaborators: Agencia Nacional de Investigación y Desarrollo
Conditions Obesity and Overweight
Enrollment 99 participants
Start Date 2025-07-21
Primary Completion 2026-06-03 (estimated)
Study Completion 2026-06-03 (estimated)
Updated on ClinicalTrials.gov 2025-11-28